Differences in #glucocorticoid dosing. In #lupus #nephritis less steroids are the same as high dose steroids. Placebo arms of pooled data from #LN #RCTs. Less is equal! #ACRbest #ACR2023 ⁦@RheumNow⁩ ⁦@ACRheum⁩ abst0781 High dose steroids tended to have lower MMF doses https://t.co/XwTlsy4xKE

Plasma MMPs and RA-ILD. Strong association MMPs 7 & 9 with prevalent RA-ILD. Abstr#0770 #ACR23 @RheumNow https://t.co/5qWeK3lAly https://t.co/SyZY2OhcbH

2 yrs extension of DRESS-PS study 100+ pts w/ PsA and AxSPA -70% LDA state in both Ctrl & Intervention gps -strong recovery after relapse No difference efficacy protocolized & routine care tapering but inferior TNFi use (52 vs. 77%) in Intervention gp @RheumNow #ACR23 ABST0775 https://t.co/V2DqCjT0w3

#ACR23 IV secukinumab vs placebo at 52 Weeks @RheumNow https://t.co/4zQa37tN4l

Abs#0608 #ACR23 @RheumNow Cenerimod: sphigosine 1-phos (S1P) 1 receptor modulator for SLE P2 CARE Study 51% of pts had high IFN1 sign., ass w/ high dsDNA Cenerimod 4 mg: decreased dsDNA and IFN-a protein at 6 mo vs b/l In high IFN pts, 4 mg Cen: decrease SLEDAI, SRI-4

Abs#595 #ACR23 @RheumNow R Furie on 4 yr TULIP-LTE pts with b/l renal involvement 33% on anifrolumab continued to wk 208 vs PBO 6% Renal improvement at w208 in 9/10 pts, vs no avail PBO data Conclusion: more Anifrolumab pts remained in study & reached SLEDAI-2K renal improvement

Cowley et al @sharoncowley01 Subclinical GCA in 17.5% with new PMR. Males with higher ESR more likely to have subclinical GCA. Subclinical GCA more axillary artery. Abstr#0747 #ACR23 #ACRbest @RheumNow https://t.co/CghmX1TKpf https://t.co/MJawtslLud

Phase 3 Study of IV Secukinumab for treatment of PsA - efficacious and safety profile similar to Subq version ~60% ACR 50 response maintained at week 52 2nd responses of MDA, PASI90, enthesitis, dactylitis resolution met @RheumNow #ACR23 Abs#0776 https://t.co/jikWd4fnGm

Entrevista de @RheumNow a las doctoras Griselda Serna Peña y Diana Flores Gutierrez sobre su trabajo de Screening y salud secual en pacientes con enfermedades reumáticas #ACR23 @SernaDra @ColMexReuma https://t.co/SyuFVXM9Sf

RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty

Reporting for @RheumNow! #ACR23 follow our coverage! @ACRheum @uptotate @Yuz6Yusof @ericdeinmd https://t.co/e4ShTzZhrE

• https://twitter.com/KDAO2011/status/1723818756466782389/photo/1